Common side effects of Proleukin include: supraventricular tachycardia, adult respiratory distress syndrome, congestive heart failure, exfoliative dermatitis, infection, pulmonary congestion, pulmonary infiltrates, respiratory tract disease, cardiac arrhythmia, edema, abdominal pain, acidosis, altered blood pressure, anemia, anxiety, asthenia, asymptomatic ecg changes, cardiovascular disorder, confusion, diarrhea, dizziness, drowsiness, dyspnea, enlargement of abdomen, fever, hyperbilirubinemia, hypocalcemia, hypomagnesemia, hypotension, increased cough, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum creatinine, leukopenia, nausea, oliguria, pain, peripheral edema, pruritus, pulmonary disease, rales, rhinitis, rhonchi, skin rash, stomatitis, tachycardia, thrombocytopenia, vasodilatation, vomiting, weight gain, anorexia, chills, and malaise.
See below for a comprehensive list of adverse effects.
As well as its needed effects, aldesleukin (the active ingredient contained in Proleukin) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking aldesleukin, check with your doctor or nurse immediately:
Some aldesleukin side effects may not need any medical attention.
As your body gets used to the medicine these side effects may disappear.
Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
-Very common (10% or more): Anti-aldesleukin (the active ingredient contained in Proleukin) antibodies (up to 74%)-Common (1% to 10%): Neutralizing antibodies
-Very common (10% or more): Hypotension (up to 71%), tachycardia (up to 23%), vasodilation (up to 13%), supraventricular tachycardia (up to 12%), cardiovascular disorder (up to 11%), arrhythmia (up to 10%), chest pain-Common (1% to 10%): Myocardial infarction, ventricular tachycardia, cardiac arrest, cyanosis, transient ECG changes, myocardial ischemia, palpitations, phlebitis, hypertension-Uncommon (0.
1% to 1%): Hemorrhage (including subdural, subarachnoid, cerebral, retroperitoneal), myocarditis, cardiomyopathy, pericardial effusion, thrombosis, thrombophlebitis-Rare (less than 0.
1%): Ventricular hypokinesia-Frequency not reported: Capillary leak syndrome, hypoperfusion, bradycardia, ventricular extrasystoles, atrial arrhythmia, second degree AV block, endocarditis, coronary artery disorder, transient ischemic attacks, pericarditis, shock-Postmarketing reports: Cardiac tamponade
Cardiovascular disorder includes fluctuations in blood pressure, asymptomatic ECG changes, cardiac failure, and congestive heart failure.
-Very common (10% or more): Diarrhea (up to 67%), vomiting (up to 50%), nausea (up to 35%), stomatitis (up to 22%), nausea with vomiting (up to 19%), abdominal pain (up to 11%), enlarged abdomen (up to 10%)-Common (1% to 10%): Dysphagia, dyspepsia, constipation, GI bleeding (including rectal hemorrhage), hematemesis, ascites, cheilitis, gastritis-Uncommon (0.
1% to 1%): Pancreatitis, intestinal obstruction, GI perforation (including necrosis/gangrene)-Rare (less than 0.
1%): Activation of quiescent Crohn's disease-Frequency not reported: GI hemorrhage, bloody diarrhea, GI disorder, intestinal perforation, duodenal ulceration, bowel necrosis, bowel perforation/infarction-Postmarketing reports: Colitis
-Very common (10% or more): Oliguria (up to 63%), increased serum creatinine (up to 33%), increased serum urea-Common (1% to 10%): Anuria, hematuria, renal failure-Frequency not reported: Increased blood urea nitrogen, crescentic IgA glomerulonephritis, acute tubular necrosis, allergic interstitial nephritis-Postmarketing reports: Increased hyperuricemia non-protein nitrogen
-Very common (10% or more): Chills (up to 52%), fever (up to 29%), peripheral edema (up to 28%), malaise (up to 27%), asthenia/fatigue (up to 23%), edema (up to 15%), infection (up to 13%), pain (up to 12%), injection site reactions, injection site necrosis, injection site pain, injection site inflammation-Common (1% to 10%): Sepsis, mucositis, injection site nodule, hypothermia-Frequency not reported: Peripheral gangrene, atypical reactions to iodinated contrast media, catheter site infections, bacterial infections, malignant hyperthermia
Lung disorder includes physical findings associated with pulmonary congestion, rales, and rhonchi.
Respiratory disorder includes acute respiratory distress syndrome (ARDS), chest x-ray infiltrates, respiratory failure, intubation, and unspecified pulmonary changes.
-Very common (10% or more): Dyspnea (up to 43%), lung disorder (up to 24%), respiratory disorder (up to 11%), increased cough (up to 11%), rhinitis (up to 10%)-Common (1% to 10%): Apnea, respiratory tract infection, lung/pulmonary edema, pleural effusion, hypoxia, hemoptysis, epistaxis, nasal congestion, rhinitis-Rare (less than 0.
1%): Pulmonary embolism-Frequency not reported: Respiratory acidosis, asthma, hyperventilation, hypoventilation, pneumothorax, trachea-esophageal fistula, respiratory arrest-Postmarketing reports: Pneumonia (bacterial, fungal, viral)
-Very common (10% or more): Erythema and rash (up to 42%), pruritus (up to 24%), exfoliative dermatitis (up to 18%), sweating-Common (1% to 10%): Urticaria, alopecia-Uncommon (0.
1% to 1%): Quincke's edema, vitiligo-Rare (less than 0.
1%): Vesiculobullous rash, Stevens-Johnson syndrome-Frequency not reported: Bullous pemphigoid, cutaneous and leukocytoplastic hypersensitivity vasculitis-Postmarketing reports: Cellulitis
-Very common (10% or more): Bilirubinemia (up to 40%), increased SGOT (up to 23%) -Common (1% to 10%): Acute kidney failure, elevation of hepatic transaminases-Uncommon (0.
1% to 1%): Hyperbilirubinemia, hepatomegaly/hepatosplenomegaly-Rare (less than 0.
1%): Cholecystitis, liver failure-Frequency not reported: Abnormal liver function tests, abnormal kidney function-Postmarketing reports: Hepatitis
-Very common (10% or more): Thrombocytopenia (up to 37%), anemia (up to 29%), leukopenia (up to 16%)-Common (1% to 10%): Coagulopathy (including disseminated intravascular coagulation), eosinophilia -Uncommon (0.
1% to 1%): Neutropenia-Rare (less than 0.
1%): Agranulocytosis, aplastic anemia, hemolytic anemia, neutropenic fever-Frequency not reported: Leukocytosis, lymphocytosis-Postmarketing reports: Lymphocytopenia
-Very common (10% or more): Confusion (up to 34%), anxiety (up to 12%), depression, insomnia-Common (1% to 10%): Psychosis, irritability, agitation, hallucinations-Frequency not reported: Paranoid reaction, delirium, suicide
-Very common (10% or more): Hypothyroidism-Common (1% to 10%): Hyperthyroidism, hyperglycemia-Uncommon (0.
1% to 1%): Hypoglycemia-Rare (less than 0.
1%): Diabetes mellitus-Frequency not reported: Thyroiditis
-Very common (10% or more): Anorexia (up to 20%), weight gain (up to 16%), acidosis (up to 12%), hypomagnesemia (up to 12%), hypocalcemia (up to 11%), increased alkaline phosphatase (up to 10%), weight loss-Common (1% to 10%): Hypercalcemia, hyperkalemia, dehydration, elevated lactic dehydrogenase
-Very common (10% or more): Somnolence (up to 22%), dizziness (up to 11%), headache, paraesthesia-Common (1% to 10%): Coma, stupor, neuropathy, syncope, speech disorders, taste loss, lethargy-Uncommon (0.
1% to 1%): Convulsions, paralysis-Rare (less than 0.
1%): Leukoencephalopathy-Frequency not reported: Grand mal convulsion, meningitis, cerebral edema, mental status changes, ataxia (limb or gait), cortical lesion, cerebral vasculitis, obtundation, cerebrovascular accident, stroke, cerebral vasculitis-Postmarketing reports: Cerebral lesions, extrapyramidal syndrome, neuralgia, neuritis, demyelinating neuropathy
Most adverse reactions were self-limited and usually reversed or improved within 1 to 3 days of therapy cessation.
However, some adverse reactions (e.
g.
, myocardial infarction, bowl perforation/infarction, gangrene) have permanent sequelae.
-Uncommon (0.
1% to 1%): Hypersensitivity reactions-Rare (less than 0.
1%): Anaphylaxis
-Common (1% to 10%): Myalgia, arthralgia-Uncommon (0.
1% to 1%): Myasthenia, myopathy, myositis-Frequency not reported: Scleroderma, inflammatory arthritis, oculobulbar myasthenia gravis-Postmarketing reports: Rhabdomyolysis
-Common (1% to 10%): Conjunctivitis-Rare (less than 0.
1%): Optic nerve disorder (including optic neuritis)-Frequency not reported: Cortical blindness, mydriasis, pupillary disorder, blindness (permanent and transient)
It is possible that some side effects of Proleukin may not have been reported.
These can be reported to the FDA here.
Always consult a healthcare professional for medical advice.
Agitation
confusion
diarrhea
dizziness
drowsiness
fever or chills
mental depression
nausea and vomiting
shortness of breath
sores in the mouth and on lips
tingling of the hands or feet
unusual decrease in urination
unusual tiredness or weakness
weight gain of 5 to 10 pounds or more
Bloating and stomach pain
blurred or double vision
faintness
fast or irregular heartbeat
loss of taste
rapid breathing
redness, swelling, and soreness of the tongue
trouble with speaking
yellow eyes and skin
Changes in menstrual periods
clumsiness
coldness
convulsions (seizures)
listlessness
muscle aches
pain or redness at injection site
sudden inability to move
swelling in the front of the neck
swelling of the feet or lower legs
weakness
Black, tarry stools
blisters on the skin
blood in the urine
bloody vomit
chest pain
cough or hoarseness
lower back or side pain
painful or difficult urination
pinpoint red spots on the skin
stomach pain (severe)
unusual bleeding or bruising
Dry skin
loss of appetite
skin rash or redness with burning or itching, followed by peeling
unusual feeling of discomfort or illness
Constipation
headache
joint pain
muscle pain